The head of Germany’s Boehringer Ingelheim has said that he “regrets” Brexit, but reassured patients in the country that the company still regards it as an important market for new drug launches.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,